Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 189 results for advanced breast cancer

  1. Gemcitabine for the treatment of metastatic breast cancer (TA116)

    Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    24 January 2007
    View recommendations

    Sections for TA116

  2. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]

    Awaiting development [GID-TA10960] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.

    Technology appraisal guidance
    Published
    10 June 2020
    View recommendations

    Sections for TA632

  4. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

    Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.

    Technology appraisal guidance
    Published
    31 January 2018
    View recommendations

    Sections for TA501

  5. Past appeals and decisions

    TA721 Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945] 3 September 2020...

  6. Cancer: breast cancer mortality rate (IND4)

    This indicator covers breast cancer mortality rates. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG04

    Network / system level indicators
    Last updated
    4 November 2020

  7. Prostate cancer: diagnosis and management (NG131)

    This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

    NICE guideline
    Last updated
    15 December 2021
    View recommendations

    Sections for NG131

  8. MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)

    NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .

    Medtech innovation briefing
    Published
    18 January 2018

  9. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    23 February 2011
    View recommendations

    Sections for TA214

  10. Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

    Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA432

  11. Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development [GID-TA11487] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)

    Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).

    Interventional procedures guidance
    Published
    22 April 2009
    View recommendations

    Sections for IPG296

  13. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update): draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 19 April 2024.

    NICE guideline
    In consultation

  14. Effectivness of 26 Gy in 5 fractions over 1 week regimen in people receiving breast construction- What is the effectiveness of radiotherapy given in 26 Gy in 5 fractions over 1 week compared with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are offered breast reconstruction?

    Effectivness of 26 Gy in 5 fractions over 1 week regimen in people receiving breast construction- What is the effectiveness of...

    Research recommendation
    Published
    7 August 2023

  15. Image-guided radiofrequency excision biopsy of breast lesions (IPG308)

    Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.

    Interventional procedures guidance
    Published
    22 July 2009
    View recommendations

    Sections for IPG308